Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BCR-ABL directed immunotherapy: a virtual reality?

O C Leeksma1, J H Kessler, I J Huijbers

  • 1Department of Immunohematology and Blood Bank, Leiden University Medical Center, The Netherlands. Leeksma@rullf2.Medfac.Leidenuniv.nl

Leukemia & Lymphoma
|May 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline mutations predisposing to diffuse large B-cell lymphoma.

Blood cancer journal·2017
Same author

Germline mutations predisposing to diffuse large B-cell lymphoma.

Blood cancer journal·2017
Same author

Betulinic acid induces a novel cell death pathway that depends on cardiolipin modification.

Oncogene·2015
Same author

T-cell regulation of human B-cell activation. A reappraisal of the role of interleukin 2.

Immunology today·2014
Same author

Betulinic acid-induced mitochondria-dependent cell death is counterbalanced by an autophagic salvage response.

Cell death & disease·2014
Same author

Anti-H-2 antibodies induced by syngeneic immunization.

Immunogenetics·2012

Specific immunotherapy for BCR-ABL (breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1) shows promise. However, research needs to confirm if the hybrid oncoprotein is processed into antigenic peptides for MHC presentation.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Targeting the BCR-ABL oncoprotein is a key strategy in chronic myeloid leukemia (CML) treatment.
  • Specific immunotherapy aims to leverage the immune system to recognize and eliminate BCR-ABL-expressing cancer cells.

Purpose of the Study:

  • To review the progress and challenges in developing BCR-ABL-specific immunotherapy.
  • To identify limitations and future research avenues for this therapeutic approach.

Main Methods:

  • Review of existing scientific literature on BCR-ABL immunotherapy.
  • Analysis of MHC-peptide binding data and antigen processing studies.

Main Results:

  • Significant progress in identifying MHC alleles capable of presenting BCR-ABL peptides.

Related Experiment Videos

  • Lack of definitive evidence for the processing of the BCR-ABL oncoprotein into relevant antigenic peptides.

    • Conclusions:

    • While MHC-peptide interactions are understood, the processing of BCR-ABL into immunogenic peptides remains a critical hurdle.
    • Further research is needed to validate antigen processing and optimize immunotherapy strategies for BCR-ABL-positive malignancies.